J&J buys Bristol-Myers Squibb’s Factor XIa inhibitor program
Category: #health  By Pankaj Singh  Date: 2018-04-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

J&J buys Bristol-Myers Squibb’s Factor XIa inhibitor program

The pharmaceutical giant Johnson & Johnson has reportedly entered into a collaboration with Bristol-Myers Squibb for the development and commercialization of Factor XIa inhibitors. The deal also provides a major stake to J&J in the development of BMS-986177 which is being prepared as a preventive drug for major thrombotic conditions.

The agreement states that Johnson & Johnson and Bristol-Myers Squibb will be advancing BMS-986177 into Phase 2 of clinical trials and establishing a comprehensive development program. The commercial profits or losses as well as the cost of development will be shared between the companies. Additional terms of the agreement were not disclosed.

The companies commented that the development of next generation of anticoagulants such as oral anticoagulants has been an important step in the treatment of thrombosis. The goal of next generation anticoagulants is to substantially lower the risk of bleeding while upholding the level and efficiency of care provided by current anticoagulants. FXla inhibition has proved through early clinical trials that it is capable of lowering risk of thrombosis and bringing down risk of bleeding when compared to currently available therapies.

With BMS-986177, Bristol-Myers has run several early-phase trials on patients with renal disease as well as healthy volunteers. The clinical trials have prepared BMS-986177 to move forward in the indication of secondary stroke prevention.

The Phase 2 trial of BMS-986177 will start in the latter half of 2018 and will be tested on patients who have previously suffered a stroke. Bristol-Myers and Johnson & Johnson are optimistic about potential application of BMS-986177 in coronary artery disease and peripheral artery as well.

The head of cardiovascular development at Bristol-Myers, Christoph Koenen has been reported to say that BMS has been enthusiastic about finding a partner for BMS-986177 asset as it has a whole range of indicators that can be too complicated to develop.

Reports cite that Johnson & Johnson’s expertise in both the fields of anticoagulation and cardiovascular disease has made Bristol-Myers highly confident of the partnership’s success.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...